Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varoglutamstat (Primary)
  • Indications Alzheimer's disease; Dementia; Mild cognitive impairment
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VIVIAD study
  • Sponsors Vivoryon Therapeutics

    • Most Recent Events

    • 01 Oct 2024 According to a Vivoryon Therapeutics media release, Vivoryon Therapeutics N.V. shares highlights from virtual kidney disease KOL event which includes observation from this trial
    • 18 Jul 2024 Results published in the Vivoryon Therapeutics Media Release
    • 23 May 2024 According to a Vivoryon Therapeutics media release, research and development expenses increased by EUR 4.3 million, which was largely attributable to the increase in clinical development costs from the VIVIAD and VIVA-MIND studies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top